메뉴 건너뛰기




Volumn 94, Issue 5, 2009, Pages 1500-1508

Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HORMONE ANTAGONIST; SOMATOSTATIN;

EID: 66149122229     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2332     Document Type: Review
Times cited : (186)

References (101)
  • 1
    • 0015914428 scopus 로고
    • Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
    • Brazeau P, Vale W, Burnus R, Ling N, Butcher M, Rivier J, Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79
    • (1973) Science , vol.179 , pp. 77-79
    • Brazeau, P.1    Vale, W.2    Burnus, R.3    Ling, N.4    Butcher, M.5    Rivier, J.6    Guillemin, R.7
  • 7
    • 0024117485 scopus 로고
    • The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors
    • Lamberts SW 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 9:417-436
    • (1988) Endocr Rev , vol.9 , pp. 417-436
    • Lamberts, S.W.1
  • 8
    • 0030295163 scopus 로고    scopus 로고
    • The pharmacological aspects of the treatment of acromegaly
    • DOI 10.1006/phrs.1996.0095
    • Giustina A, Zaltieri G, Negrini F, Wehrenberg WB 1996 The pharmacological aspects of the treatment of acromegaly. Pharmacol Res 34:247-268 (Pubitemid 27095820)
    • (1996) Pharmacological Research , vol.34 , Issue.5-6 , pp. 247-268
    • Giustina, A.1    Zaltieri, G.2    Negrini, F.3    Wehrenberg, W.B.4
  • 9
    • 2942675021 scopus 로고    scopus 로고
    • The diagnosis and medical management of advanced neuroendocrine tumors
    • DOI 10.1210/er.2003-0014
    • Kaltsas GA, Besser GM, Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511 (Pubitemid 38780668)
    • (2004) Endocrine Reviews , vol.25 , Issue.3 , pp. 458-511
    • Kaltsas, G.A.1    Besser, G.M.2    Grossman, A.B.3
  • 10
    • 33846813582 scopus 로고    scopus 로고
    • A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours
    • DOI 10.1517/13543784.16.2.219
    • Strosberg JR, Kvols LK 2007 A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 16:219-224 (Pubitemid 46206635)
    • (2007) Expert Opinion on Investigational Drugs , vol.16 , Issue.2 , pp. 219-224
    • Strosberg, J.R.1    Kvols, L.K.2
  • 11
    • 0029583845 scopus 로고
    • Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation
    • Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, Leung VK, Li MK, Li AK 1995 Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 346:1666-1669 (Pubitemid 26003324)
    • (1995) Lancet , vol.346 , Issue.8991-8992 , pp. 1666-1669
    • Sung, J.J.Y.1    Chung, S.C.S.2    Yung, M.Y.3    Lai, C.W.4    Lau, J.Y.W.5    Lee, Y.T.6    Leung, V.K.S.7    Li, M.K.K.8    Li, A.K.C.9
  • 12
    • 0031776784 scopus 로고    scopus 로고
    • Somatostatin analogues in the treatment of thyroid eye disease
    • Krassas GE 1998 Somatostatin analogues in the treatment of thyroid eye disease. Thyroid 8:443-445 (Pubitemid 28252432)
    • (1998) Thyroid , vol.8 , Issue.5 , pp. 443-445
    • Krassas, G.E.1
  • 14
    • 0141557668 scopus 로고    scopus 로고
    • Review article: Pharmacological rationale for the use of somatostatin and analogues in portal hypertension
    • DOI 10.1046/j.1365-2036.2003.01657.x
    • Reynaert H, Geerts A 2003 Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 18:375-386 (Pubitemid 37070235)
    • (2003) Alimentary Pharmacology and Therapeutics , vol.18 , Issue.4 , pp. 375-386
    • Reynaert, H.1    Geerts, A.2
  • 17
    • 33947537660 scopus 로고    scopus 로고
    • Use of long-acting somatostatin analogue treatment in diabetic retinopathy
    • Boehm BO 2007 Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol 39:111-121
    • (2007) Dev Ophthalmol , vol.39 , pp. 111-121
    • Boehm, B.O.1
  • 18
    • 0025988239 scopus 로고
    • Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin
    • Giustina A, Girelli A, Buffoli MG, Cimino A, Legati F, Valentini U, Giustina G 1991 Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 14:47-54.
    • (1991) Diabetes Res Clin Pract , vol.14 , pp. 47-54
    • Giustina, A.1    Girelli, A.2    Buffoli, M.G.3    Cimino, A.4    Legati, F.5    Valentini, U.6    Giustina, G.7
  • 19
    • 12344298281 scopus 로고    scopus 로고
    • Pharmacologic therapies for acromegaly: A review of their effects on glucose metabolism and insulin resistance
    • DOI 10.2165/00024677-200504010-00005
    • Pereira AM, Biermasz NR, Roelfsema F, Romijn JA 2005 Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43-53 (Pubitemid 40129110)
    • (2005) Treatments in Endocrinology , vol.4 , Issue.1 , pp. 43-53
    • Pereira, A.M.1    Biermasz, N.R.2    Roelfsema, F.3    Romijn, J.A.4
  • 21
    • 1442326975 scopus 로고    scopus 로고
    • Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
    • DOI 10.1210/er.2002-0022
    • Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152 (Pubitemid 38269977)
    • (2004) Endocrine Reviews , vol.25 , Issue.1 , pp. 102-152
    • Colao, A.1    Ferone, D.2    Marzullo, P.3    Lombardi, G.4
  • 25
    • 0023110899 scopus 로고
    • Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995)
    • Sandler LM, Burrin JM, Williams G, Joplin GF, Carr DH, Bloom SR 1987 Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995). Clin Endocrinol (Oxf) 26:85-95 (Pubitemid 17015969)
    • (1987) Clinical Endocrinology , vol.26 , Issue.1 , pp. 85-95
    • Sandler, L.M.1    Burrin, J.M.2    Williams, G.3
  • 27
    • 0025164701 scopus 로고
    • Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group
    • Sassolas G, Harris AG, James-Deidier A 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 71:391-397
    • (1990) J Clin Endocrinol Metab , vol.71 , pp. 391-397
    • Sassolas, G.1    Harris, A.G.2    James-Deidier, A.3
  • 30
    • 0025190143 scopus 로고
    • Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety
    • Ho KY, Weissberger AJ, Marbach P, Lazarus L 1990 Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med 112:173-181
    • (1990) Ann Intern Med , vol.112 , pp. 173-181
    • Ho, K.Y.1    Weissberger, A.J.2    Marbach, P.3    Lazarus, L.4
  • 31
    • 0025895476 scopus 로고
    • Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide
    • James RA, Møller N, Chatterjee S, White M, Kendall-Taylor P 1991 Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med 8:517-523
    • (1991) Diabet Med , vol.8 , pp. 517-523
    • James, R.A.1    Møller, N.2    Chatterjee, S.3    White, M.4    Kendall-Taylor, P.5
  • 32
    • 0025783499 scopus 로고
    • Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group
    • Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 151:1573-1578
    • (1991) Arch Intern Med , vol.151 , pp. 1573-1578
    • Vance, M.L.1    Harris, A.G.2
  • 33
    • 0026560276 scopus 로고
    • Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly
    • (Oxf)
    • Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271-279
    • (1992) Clin Endocrinol , vol.36 , pp. 271-279
    • Ho, K.K.1    Jenkins, A.B.2    Furler, S.M.3    Borkman, M.4    Chisholm, D.J.5
  • 35
    • 0027741436 scopus 로고
    • Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly
    • Lam KS, Pang RW, Janus ED, Kung AW, Wang CC 1993 Serum apolipoprotein (a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 104:183-188 (Pubitemid 24035646)
    • (1993) Atherosclerosis , vol.104 , Issue.1-2 , pp. 183-188
    • Lam, K.S.L.1    Pang, R.W.C.2    Janus, E.D.3    Kung, A.W.C.4    Wang, C.C.L.5
  • 36
    • 0027168793 scopus 로고
    • Octreotide long term treatment of acromegaly: Effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values
    • DOI 10.1210/jc.77.1.157
    • Plöckinger U, Liehr RM, Quabbe HJ 1993 Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values. J Clin Endocrinol Metab 77:157-162 (Pubitemid 23206795)
    • (1993) Journal of Clinical Endocrinology and Metabolism , vol.77 , Issue.1 , pp. 157-162
    • Plockinger, U.1    Liehr, R.-M.2    Quabbe, H.-J.3
  • 42
    • 0028822452 scopus 로고
    • Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase
    • Simsolo RB, Ezzat S, Ong JM, Saghizadeh M, Kern PA 1995 Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. J Clin Endocrinol Metab 80:3233-3238
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 3233-3238
    • Simsolo, R.B.1    Ezzat, S.2    Ong, J.M.3    Saghizadeh, M.4    Kern, P.A.5
  • 43
    • 0029586762 scopus 로고
    • Short-term effects of octreotide on glucose tolerance in patients with acromegaly
    • Sato K, Takamatsu K, Hashimoto K 1995 Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocr J 42:739-745 (Pubitemid 26038687)
    • (1995) Endocrine Journal , vol.42 , Issue.6 , pp. 739-745
    • Sato, K.1    Takamatsu, K.2    Hashimoto, K.3
  • 44
    • 0028882919 scopus 로고
    • Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study
    • Italian Multicenter Octreotide Study Group.
    • Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G 1995 Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133:430-439
    • (1995) Eur J Endocrinol , vol.133 , pp. 430-439
    • Arosio, M.1    Macchelli, S.2    Rossi, C.M.3    Casati, G.4    Biella, O.5    Faglia, G.6
  • 45
    • 0029804842 scopus 로고    scopus 로고
    • The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
    • al-Maskari M, Gebbie J, Kendall-Taylor P 1996 The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol 45:415-421
    • (1996) Clin Endocrinol , vol.45 , pp. 415-421
    • Al-Maskari, M.1    Gebbie, J.2    Kendall-Taylor, P.3
  • 48
    • 0031930952 scopus 로고    scopus 로고
    • Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
    • DOI 10.1046/j.1365-2265.1998.00389.x
    • Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM 1998 Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol 48:311-316 (Pubitemid 28137643)
    • (1998) Clinical Endocrinology , vol.48 , Issue.3 , pp. 311-316
    • Davies, P.H.1    Stewart, S.E.2    Lancranjan, I.3    Sheppard, M.C.4    Stewart, P.M.5
  • 49
    • 0033291744 scopus 로고    scopus 로고
    • Results of a European multicentre study with Sandostatin LAR in acromegalic patients
    • Sandostatin LAR Group
    • Lancranjan I, Atkinson AB 1999 Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1:105-114
    • (1999) Pituitary , vol.1 , pp. 105-114
    • Lancranjan, I.1    Atkinson, A.B.2
  • 50
    • 0032828008 scopus 로고    scopus 로고
    • A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
    • DOI 10.1530/eje.0.1410267
    • Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G 1999 A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 141:267-271 (Pubitemid 29465932)
    • (1999) European Journal of Endocrinology , vol.141 , Issue.3 , pp. 267-271
    • Cozzi, R.1    Dallabonzana, D.2    Attanasio, R.3    Barausse, M.4    Oppizzi, G.5
  • 52
    • 0034433176 scopus 로고    scopus 로고
    • Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly
    • Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M 2000 Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 3:61-65
    • (2000) Pituitary , vol.3 , pp. 61-65
    • Kendall-Taylor, P.1    Miller, M.2    Gebbie, J.3    Turner, S.4    Al-Maskari, M.5
  • 53
    • 0035000997 scopus 로고    scopus 로고
    • Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide
    • Díez JJ, Iglesias P, Gó mez-Pan A 2001 Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. J Endocrinol Invest 24:303-309
    • (2001) J Endocrinol Invest , vol.24 , pp. 303-309
    • Díez, J.J.1    Iglesias, P.2    Gómez-Pan, A.3
  • 56
    • 0036738337 scopus 로고    scopus 로고
    • Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly
    • Ayuk J, Stewart SE, Stewart PM, Sheppard MC 2002 Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87:4142-4146
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4142-4146
    • Ayuk, J.1    Stewart, S.E.2    Stewart, P.M.3    Sheppard, M.C.4
  • 68
    • 23244442834 scopus 로고    scopus 로고
    • Treatment of acromegaly with octreotide-LAR: Extensive experience in a Brazilian institution
    • DOI 10.1111/j.1365-2265.2005.02317.x
    • Jallad RS, Musolino NR, Salgado LR, Bronstein MD 2005 Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168-175 (Pubitemid 41097985)
    • (2005) Clinical Endocrinology , vol.63 , Issue.2 , pp. 168-175
    • Jallad, R.S.1    Musolino, N.R.C.2    Salgado, L.R.3    Bronstein, M.D.4
  • 69
    • 33645025605 scopus 로고    scopus 로고
    • Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly
    • (Oxf)
    • Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM 2006 Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209-214
    • (2006) Clin Endocrinol , vol.64 , pp. 209-214
    • Caron, P.1    Cogne, M.2    Raingeard, I.3    Bex-Bachellerie, V.4    Kuhn, J.M.5
  • 71
    • 35848967790 scopus 로고    scopus 로고
    • Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA
    • DOI 10.1007/s11102-007-0037-7
    • De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A 2007 Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227-232 (Pubitemid 350055033)
    • (2007) Pituitary , vol.10 , Issue.3 , pp. 227-232
    • De Marinis, L.1    Bianchi, A.2    Fusco, A.3    Cimino, V.4    Mormando, M.5    Tilaro, L.6    Mazziotti, G.7    Pontecorvi, A.8    Giustina, A.9
  • 72
    • 34447513998 scopus 로고    scopus 로고
    • Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
    • DOI 10.1111/j.1365-2265.2007.02878.x
    • Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P 2007 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67:282-289 (Pubitemid 47076308)
    • (2007) Clinical Endocrinology , vol.67 , Issue.2 , pp. 282-289
    • Maiza, J.C.1    Vezzosi, D.2    Matta, M.3    Donadille, F.4    Loubes-Lacroix, F.5    Cournot, M.6    Bennet, A.7    Caron, P.8
  • 75
    • 84948773232 scopus 로고    scopus 로고
    • Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
    • Egger M, Smith GD, Altman DG, eds. London: BMJ Publishing Group
    • Deeks JJ, Altman DG, Bradburn MJ 2001 Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in healthcare: metaanalysis in context. 2nd ed. London: BMJ Publishing Group; 285-312
    • (2001) Systematic Reviews in Healthcare: Metaanalysis in Context. 2nd Ed. , pp. 285-312
    • Deeks, J.J.1    Altman, D.G.2    Bradburn, M.J.3
  • 76
    • 0037098199 scopus 로고    scopus 로고
    • Quantifying heterogeneity in a meta-analysis
    • DOI 10.1002/sim.1186
    • Higgins JP, Thompson SG 2002 Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558 (Pubitemid 34746062)
    • (2002) Statistics in Medicine , vol.21 , Issue.11 , pp. 1539-1558
    • Higgins, J.P.T.1    Thompson, S.G.2
  • 78
    • 0025700486 scopus 로고
    • Medical progress: Acromegaly
    • Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355:2558-2573 (Pubitemid 20146631)
    • (1990) New England Journal of Medicine , vol.322 , Issue.14 , pp. 966-977
    • Melmed, S.1
  • 80
    • 0032239547 scopus 로고    scopus 로고
    • Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human
    • Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797 (Pubitemid 128506521)
    • (1998) Endocrine Reviews , vol.19 , Issue.6 , pp. 717-797
    • Giustina, A.1    Veldhuis, J.D.2
  • 81
    • 0038813735 scopus 로고    scopus 로고
    • Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly
    • DOI 10.1023/A:1023321421760
    • Clemmons DR 2002 Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181-183 (Pubitemid 36656431)
    • (2002) Pituitary , vol.5 , Issue.3 , pp. 181-183
    • Clemmons, D.R.1
  • 82
    • 48349128492 scopus 로고    scopus 로고
    • Contribution of gluconeogenesis and glycogenolysis to hepatic glucose production in acromegaly before and after pituitary microsurgery
    • Höybye C, Chandramouli V, Efendic S, Hulting AL, Landau BR, Schumann WC, Wajngot A 2008 Contribution of gluconeogenesis and glycogenolysis to hepatic glucose production in acromegaly before and after pituitary microsurgery. Horm Metab Res 40:498-501
    • (2008) Horm Metab Res , vol.40 , pp. 498-501
    • Höybye, C.1    Chandramouli, V.2    Efendic, S.3    Hulting, A.L.4    Landau, B.R.5    Schumann, W.C.6    Wajngot, A.7
  • 84
    • 25444517599 scopus 로고    scopus 로고
    • Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women
    • Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A 2005 Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-1844
    • (2005) J Bone Miner Res , vol.20 , pp. 1837-1844
    • Bonadonna, S.1    Mazziotti, G.2    Nuzzo, M.3    Bianchi, A.4    Fusco, A.5    De Marinis, L.6    Giustina, A.7
  • 86
    • 49549111375 scopus 로고    scopus 로고
    • Growth hormone, insulin-like growth factors, and the skeleton
    • Giustina A, Mazziotti G, Canalis E 2008 Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559
    • (2008) Endocr Rev , vol.29 , pp. 535-559
    • Giustina, A.1    Mazziotti, G.2    Canalis, E.3
  • 87
    • 0034465470 scopus 로고    scopus 로고
    • Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice
    • Strowski MZ, Parmar RM, Blake AD, Schaeffer JM 2000 Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117
    • (2000) Endocrinology , vol.141 , pp. 111-117
    • Strowski, M.Z.1    Parmar, R.M.2    Blake, A.D.3    Schaeffer, J.M.4
  • 88
    • 33746273283 scopus 로고    scopus 로고
    • Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly
    • DOI 10.1530/eje.1.02185
    • Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J 2006 Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73-78 (Pubitemid 44103377)
    • (2006) European Journal of Endocrinology , vol.155 , Issue.1 , pp. 73-78
    • Steffin, B.1    Gutt, B.2    Bidlingmaier, M.3    Dieterle, C.4    Oltmann, F.5    Schopohl, J.6
  • 90
    • 0036800303 scopus 로고    scopus 로고
    • Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
    • DOI 10.1210/er.2001-0022
    • Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
    • (2002) Endocrine Reviews , vol.23 , Issue.5 , pp. 623-646
    • Kopchick, J.J.1    Parkinson, C.2    Stevens, E.C.3    Trainer, P.J.4
  • 92
    • 0034037529 scopus 로고    scopus 로고
    • Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients
    • DOI 10.1046/j.1365-2265.2000.00986.x
    • Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N 2000 Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549-555 (Pubitemid 30337079)
    • (2000) Clinical Endocrinology , vol.52 , Issue.5 , pp. 549-555
    • Kasayama, S.1    Otsuki, M.2    Takagi, M.3    Saito, H.4    Sumitani, S.5    Kouhara, H.6    Koga, M.7    Saitoh, Y.8    Ohnishi, T.9    Arita, N.10
  • 93
    • 0021906772 scopus 로고
    • Production of insulin resistance by hyperinsulinaemia in man
    • Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE 1985 Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 28:70-75 (Pubitemid 15128811)
    • (1985) Diabetologia , vol.28 , Issue.2 , pp. 70-75
    • Rizza, R.A.1    Mandarino, L.J.2    Genest, J.3
  • 95
    • 0022354853 scopus 로고
    • Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
    • Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E 1985 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576-1580 (Pubitemid 16177397)
    • (1985) New England Journal of Medicine , vol.313 , Issue.25 , pp. 1576-1580
    • Lamberts, S.W.J.1    Uitterlinden, P.2    Verschoor, L.3
  • 99
    • 0346728594 scopus 로고    scopus 로고
    • Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant
    • DOI 10.1530/eje.0.1490521
    • Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ 2003 Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527 (Pubitemid 38054695)
    • (2003) European Journal of Endocrinology , vol.149 , Issue.6 , pp. 521-527
    • Drake, W.M.1    Rowles, S.V.2    Roberts, M.E.3    Fode, F.K.4    Besser, G.M.5    Monson, J.P.6    Trainer, P.J.7
  • 101
    • 33645221483 scopus 로고    scopus 로고
    • Efficacy of 12-month treatment with theGHreceptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance
    • Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with theGHreceptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
    • (2006) Eur J Endocrinol , vol.154 , pp. 467-477
    • Colao, A.1    Pivonello, R.2    Auriemma, R.S.3    De Martino, M.C.4    Bidlingmaier, M.5    Briganti, F.6    Tortora, F.7    Burman, P.8    Kourides, I.A.9    Strasburger, C.J.10    Lombardi, G.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.